Published in J Immunol on October 01, 1985
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg (1989) 3.58
Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J Clin Invest (1991) 2.37
Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest (1993) 2.18
Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood (2009) 2.00
Suppression of murine allergic airway disease by IL-2:anti-IL-2 monoclonal antibody-induced regulatory T cells. J Immunol (2008) 1.58
Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature. Proc Natl Acad Sci U S A (2013) 1.58
Interleukin-2 is present in human blood vessels and released in biologically active form by heparanase. Immunol Cell Biol (2011) 1.45
Agents that increase AAM differentiation blunt RSV-mediated lung pathology. J Leukoc Biol (2014) 1.39
Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther (2008) 1.38
Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity. J Exp Med (1989) 1.35
Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest (1990) 1.22
The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. Ann Surg (1988) 1.21
Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci U S A (1996) 1.20
Study of the biological activities of toxic shock syndrome toxin-1: II. Induction of the proliferative response and the interleukin 2 production by T cells from human peripheral blood mononuclear cells stimulated with the toxin. Clin Exp Immunol (1987) 1.19
Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc Natl Acad Sci U S A (1993) 1.10
Comparison of interferon-γ-, interleukin (IL)-17- and IL-22-expressing CD4 T cells, IL-22-expressing granulocytes and proinflammatory cytokines during latent and active tuberculosis infection. Clin Exp Immunol (2012) 1.10
The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. Am J Pathol (1987) 1.07
Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res (2012) 1.06
Postoperative enteritis caused by methicillin-resistant Staphylococcus aureus. Surg Today (1997) 1.03
Modulation of cellular immune responses in mice with disseminated histoplasmosis by recombinant interleukin-2. Infect Immun (1986) 1.03
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res (2015) 1.02
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases. Clin Cancer Res (2015) 0.99
Relative strength of the mitogenic and interleukin-2-production-inducing activities of staphylococcal exotoxins presumed to be causative exotoxins of toxic shock syndrome: toxic shock syndrome toxin-1 and enterotoxins A, B and C to murine and human T cells. Clin Exp Immunol (1989) 0.97
Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia. J Exp Med (1989) 0.97
IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study. PLoS One (2011) 0.97
Administration in vivo of recombinant interleukin 2 protects mice against septic death. J Clin Invest (1987) 0.93
A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects. Br J Cancer (1993) 0.90
Evaluation of the effect of continuous infusion recombinant interleukin-2 (bioleukin) on peripheral blood leucocytes of patients with terminal malignancy. Br J Cancer (1989) 0.85
Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol (2014) 0.84
Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy. J Clin Invest (1992) 0.83
Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases. Cancer Gene Ther (2014) 0.83
The clinical potential of interleukin-2. Br J Cancer (1988) 0.82
Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2. Clin Exp Immunol (1993) 0.82
Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy (2014) 0.81
Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2. Br J Cancer (1992) 0.81
Transgenic mice in the study of cytokine function. Int J Exp Pathol (1993) 0.81
IL-4 acts as a homeostatic regulator of IL-2-induced TNF and IFN-gamma. Immunology (1991) 0.81
Opposite effects of interleukin-2 on normal and transfusion-suppressed healing of experimental intestinal anastomoses. Ann Surg (1993) 0.81
Enhancement of a delayed hypersensitivity reaction to a contact allergen, by the systemic administration of interleukin-2. Immunology (1991) 0.80
Lysis of primary hepatic tumours by lymphokine activated killer cells. Gut (1987) 0.80
Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells. Gut (1987) 0.79
Taurine attenuates CD3/interleukin-2-induced T cell apoptosis in an in vitro model of activation-induced cell death (AICD). Clin Exp Immunol (2005) 0.79
A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects. Br J Cancer (1992) 0.79
Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2. Clin Exp Immunol (1988) 0.78
Clinical and immunological effects of single bolus administration of recombinant interleukin-2 in cattle. Can J Vet Res (1992) 0.78
Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model. Vaccine (2013) 0.78
Inhibition of G-protein βγ signaling enhances T cell receptor-stimulated interleukin 2 transcription in CD4+ T helper cells. PLoS One (2015) 0.77
Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines. Br J Cancer (1997) 0.76
Involvement of thromboxane and neutrophils in multiple-system organ edema with interleukin-2. Ann Surg (1990) 0.76
Influence of LAK cells on expression of HLA-DR antigen on laryngeal carcinoma cell line in new culture systems. Eur Arch Otorhinolaryngol (1993) 0.75
Tumor infiltrating lymphocytes. J Natl Med Assoc (1990) 0.75
Oligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2. J Immunol (2013) 0.75
The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment. Bull N Y Acad Med (1989) 0.75
Lymphokine-activated killer (LAK) cells modulate the effects of IL-2 on a T cell-mediated immune response. Clin Exp Immunol (1991) 0.75
Endogenous substances as drugs. Issues related to the application of cytokines in cancer therapy. Drug Saf (1990) 0.75
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer (2017) 0.75
Effects of immunization with tumor cells double transfected with interleukin-2 (IL-2) and interleukin-12 (IL-12) genes on artificial metastasis of colon26 cells in BALB/c mice. Clin Exp Metastasis (1999) 0.75
IL-2 induces the release of secondary cytokines which stimulate the cytotoxic activity of either NK or CD8(+) lymphocytes. Cytotechnology (1991) 0.75
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A (1994) 8.92
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med (1988) 8.90
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med (1982) 8.74
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 8.07
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst (1994) 7.20
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A (1994) 6.93
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 6.36
The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ (2011) 5.95
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother (2001) 5.83
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol (1998) 5.74
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol (1989) 5.44
Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med (1990) 5.27
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science (1984) 4.90
Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases. Cancer (1973) 4.66
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am (2000) 4.19
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med (1994) 3.94
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66
Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol (1989) 3.60
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg (1989) 3.58
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol (1996) 3.45
Expression of interleukin 2 receptors on activated human B cells. J Exp Med (1984) 3.27
Identification of human cancers deficient in antigen processing. J Exp Med (1993) 3.21
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods (1987) 3.09
Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (1984) 3.08
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med (1997) 3.07
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med (1985) 3.05
Determination of surface antigens on highly purified human NK cells by flow cytometry with monoclonal antibodies. J Immunol (1981) 3.05
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol (2001) 3.05
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol (1998) 3.03
Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol (1987) 3.03
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med (1996) 2.99
Cell cycle of Saccharomycescerevisiae in populations growing at different rates. Proc Natl Acad Sci U S A (1977) 2.96
The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med (1984) 2.95
NIH conference. Hepatocellular carcinoma. Ann Intern Med (1988) 2.94
High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol (1999) 2.94
The value of laparotomy and splenectomy in the staging of Hodgkin's disease. Cancer (1969) 2.93
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med (1996) 2.92
Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins. J Clin Invest (1983) 2.91
HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene (2010) 2.91
HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia (2010) 2.83
Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol (1986) 2.82
Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res (1994) 2.74
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am (1997) 2.71
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med (1996) 2.69
Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med (1983) 2.67
Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med (1995) 2.54
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res (1981) 2.49
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol (1995) 2.45
B-lymphocyte heterogeneity: development and characterization of an alloantiserum which distinguishes B-lymphocyte differentiation alloantigens. J Exp Med (1977) 2.44
Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med (1982) 2.42
Monocyte dependence of pokeweed mitogen-induced differentiation of immunoglobulin-secreting cells from human peripheral blood mononuclear cells. J Immunol (1979) 2.36
Passive immunotherapy of cancer in animals and man. Adv Cancer Res (1977) 2.32
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med (1996) 2.31
The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ (2009) 2.30
An Lyt differentiated thymocyte subpopulation detected by flow microfluorometry. Nature (1979) 2.29
Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules: a prospective radiologic-pathologic study. AJR Am J Roentgenol (1978) 2.29
A mouse IgM allotypic determinant (Igh-6.5) recognized by a monoclonal rat antibody. J Immunol (1981) 2.27
Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med (1988) 2.26
Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol (1996) 2.24
Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol (1992) 2.19
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol (1999) 2.17
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst (1998) 2.17
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17
Surgical staging of abdominal involvement in unselected patients with Hodgkin's disease. Radiology (1970) 2.16
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol (1996) 2.15
Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am (1998) 2.14
Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med (1991) 2.14
The fate of interleukin-2 after in vivo administration. J Immunol (1983) 2.13
Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol (1995) 2.12
Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci U S A (1997) 2.11
Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst (1996) 2.11
T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Cancer J (2001) 2.08
Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol (1986) 2.08
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 2.08